New Method Helps Rule Out Heart Valve Infection
By LabMedica International staff writers Posted on 08 Nov 2017 |

Image: A scanning electron photomicrograph of Streptococcus mutans; these bacteria are found in cases of infective endocarditis (Photo courtesy of Dr. David Phillips).
If a blood sample shows the presence of what is known as alpha-streptococci, there is a risk that the person suffers from infective endocarditis, a heart valve infection and it is an inflammation of the inner tissues of the heart, the endocardium, usually of the valves.
In order to determine whether or not this is the case, the patient must undergo echocardiography, a type of ultrasound examination of the heart, which can be technically difficult to implement and is often unpleasant. Previously, there has been a lack of supporting documentation and evidence to help healthcare professionals determine when such an examination is to be performed on patients.
Clinical scientists at Lund University (Lund, Sweden) developed a risk assessment system, HANDOC, which distinguishes which patients with alpha-streptococci in the blood who are either at high and low risk respectively of suffering from infective endocarditis (IE). The study was based on medical records from 340 adult patients in Skåne University Hospital (Lund, Sweden), whose blood samples showed the presence of alpha-streptococci. In 26 of them, infective endocarditis was confirmed. The investigators mapped the factors that distinguished these patients from those who were not diagnosed with infective endocarditis. Based on the result, an assessment system was constructed.
The investigators found that several factors differed significantly between the patients with IE and those without. Amongst these variables, the presence of heart murmur or valve disease, etiology with the groups of Streptococcus mutans, S. bovis, S. sanguinis or S. anginosus, number of positive blood cultures equal to or greater than two, duration of symptoms of seven days or more, only one species growing in blood cultures, and community acquired infection were chosen to form the HANDOC score. With a cut-off between two and three points, HANDOC had a sensitivity of 100% and specificity of 73% in the first cohort. When tested in the validation cohort, the sensitivity was 100% and the specificity 76%.
Magnus Rasmussen, MD, PhD, an associate professor and senior author of the study, said, “Clinical microbiology has taken strides when it comes to determining bacterial strains, but it's not always clear what this information will mean to the care of the patients. With this assessment system, we have created an easy-to-use tool systematizing how clinicians should treat patients with alpha-streptococci in the blood.” The study was published on October 10, 2017, in the journal Clinical Infectious Diseases.
Related Links:
Lund University
Skåne University Hospital
In order to determine whether or not this is the case, the patient must undergo echocardiography, a type of ultrasound examination of the heart, which can be technically difficult to implement and is often unpleasant. Previously, there has been a lack of supporting documentation and evidence to help healthcare professionals determine when such an examination is to be performed on patients.
Clinical scientists at Lund University (Lund, Sweden) developed a risk assessment system, HANDOC, which distinguishes which patients with alpha-streptococci in the blood who are either at high and low risk respectively of suffering from infective endocarditis (IE). The study was based on medical records from 340 adult patients in Skåne University Hospital (Lund, Sweden), whose blood samples showed the presence of alpha-streptococci. In 26 of them, infective endocarditis was confirmed. The investigators mapped the factors that distinguished these patients from those who were not diagnosed with infective endocarditis. Based on the result, an assessment system was constructed.
The investigators found that several factors differed significantly between the patients with IE and those without. Amongst these variables, the presence of heart murmur or valve disease, etiology with the groups of Streptococcus mutans, S. bovis, S. sanguinis or S. anginosus, number of positive blood cultures equal to or greater than two, duration of symptoms of seven days or more, only one species growing in blood cultures, and community acquired infection were chosen to form the HANDOC score. With a cut-off between two and three points, HANDOC had a sensitivity of 100% and specificity of 73% in the first cohort. When tested in the validation cohort, the sensitivity was 100% and the specificity 76%.
Magnus Rasmussen, MD, PhD, an associate professor and senior author of the study, said, “Clinical microbiology has taken strides when it comes to determining bacterial strains, but it's not always clear what this information will mean to the care of the patients. With this assessment system, we have created an easy-to-use tool systematizing how clinicians should treat patients with alpha-streptococci in the blood.” The study was published on October 10, 2017, in the journal Clinical Infectious Diseases.
Related Links:
Lund University
Skåne University Hospital
Latest Microbiology News
- Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
- New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
- Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
- Innovative ID/AST System to Help Diagnose Infectious Diseases and Combat AMR
- Gastrointestinal Panel Delivers Rapid Detection of Five Common Bacterial Pathogens for Outpatient Use
- Rapid PCR Testing in ICU Improves Antibiotic Stewardship
- Unique Genetic Signature Predicts Drug Resistance in Bacteria
- Unique Barcoding System Tracks Pneumonia-Causing Bacteria as They Infect Blood Stream
- Rapid Sepsis Diagnostic Test Demonstrates Improved Patient Care and Cost Savings in Hospital Application
- Rapid Diagnostic System to Detect Neonatal Sepsis Within Hours
- Novel Test to Diagnose Bacterial Pneumonia Directly from Whole Blood
- Interferon-γ Release Assay Effective in Patients with COPD Complicated with Pulmonary Tuberculosis
- New Point of Care Tests to Help Reduce Overuse of Antibiotics
- 30-Minute Sepsis Test Differentiates Bacterial Infections, Viral Infections, and Noninfectious Disease
- CRISPR-TB Blood Test to Enable Early Disease Diagnosis and Public Screening
- Syndromic Panel Provides Fast Answers for Outpatient Diagnosis of Gastrointestinal Conditions
Channels
Clinical Chemistry
view channel
‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more
Low-Cost Portable Screening Test to Transform Kidney Disease Detection
Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more
New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read moreMolecular Diagnostics
view channel
Blood Biomarker Test Could Detect Genetic Predisposition to Alzheimer’s
New medications for Alzheimer’s disease, the most common form of dementia, are now becoming available. These treatments, known as “amyloid antibodies,” work by promoting the removal of small deposits from... Read more
Novel Autoantibody Against DAGLA Discovered in Cerebellitis
Autoimmune cerebellar ataxias are strongly disabling disorders characterized by an impaired ability to coordinate muscle movement. Cerebellar autoantibodies serve as useful biomarkers to support rapid... Read more
Gene-Based Blood Test Accurately Predicts Tumor Recurrence of Advanced Skin Cancer
Melanoma, an aggressive form of skin cancer, becomes extremely difficult to treat once it spreads to other parts of the body. For patients with metastatic melanoma tumors that cannot be surgically removed... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read morePathology
view channel
Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures
Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more
New Error-Corrected Method to Help Detect Cancer from Blood Samples Alone
"Liquid biopsy" technology, which relies on blood tests for early cancer detection and monitoring cancer burden in patients, has the potential to transform cancer care. However, detecting the mutational... Read more
"Metal Detector" Algorithm Hunts Down Vulnerable Tumors
Scientists have developed an algorithm capable of functioning as a "metal detector" to identify vulnerable tumors, marking a significant advancement in personalized cancer treatment. This breakthrough... Read more
Novel Technique Uses ‘Sugar’ Signatures to Identify and Classify Pancreatic Cancer Cell Subtypes
Pancreatic cancer is often asymptomatic in its early stages, making it difficult to detect until it has progressed. Consequently, only 15% of pancreatic cancers are diagnosed early enough to allow for... Read moreTechnology
view channel
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more